GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Cyclically Adjusted PB Ratio

Genetic Technologies (Genetic Technologies) Cyclically Adjusted PB Ratio : 0.09 (As of Apr. 27, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Genetic Technologies's current share price is $2.221. Genetic Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $24.18. Genetic Technologies's Cyclically Adjusted PB Ratio for today is 0.09.

The historical rank and industry rank for Genetic Technologies's Cyclically Adjusted PB Ratio or its related term are showing as below:

GENE' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.07   Med: 0.62   Max: 2.18
Current: 0.09

During the past years, Genetic Technologies's highest Cyclically Adjusted PB Ratio was 2.18. The lowest was 0.07. And the median was 0.62.

GENE's Cyclically Adjusted PB Ratio is ranked better than
92.37% of 131 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.98 vs GENE: 0.09

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Genetic Technologies's adjusted book value per share data for the three months ended in Dec. 2023 was $0.837. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $24.18 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genetic Technologies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Genetic Technologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Cyclically Adjusted PB Ratio Chart

Genetic Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.17 0.34 0.14 0.16

Genetic Technologies Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 - 0.16 - 0.10

Competitive Comparison of Genetic Technologies's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Genetic Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Technologies's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Cyclically Adjusted PB Ratio falls into.



Genetic Technologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Genetic Technologies's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.221/24.18
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Genetic Technologies's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.837/125.6559*125.6559
=0.837

Current CPI (Dec. 2023) = 125.6559.

Genetic Technologies Quarterly Data

Book Value per Share CPI Adj_Book
200812 92.489 85.814 135.430
200906 83.714 86.278 121.921
200912 60.609 87.578 86.961
201006 32.699 88.971 46.181
201012 67.758 89.993 94.609
201106 48.574 92.129 66.251
201112 87.501 92.686 118.626
201203 0.000 92.779 0.000
201206 85.752 93.244 115.560
201212 66.557 94.730 88.286
201303 0.000 95.101 0.000
201306 31.353 95.473 41.265
201312 31.462 97.330 40.618
201406 7.808 98.352 9.976
201412 0.825 99.002 1.047
201506 23.880 99.838 30.055
201512 18.898 100.673 23.588
201606 14.358 100.859 17.888
201612 12.426 102.159 15.284
201706 9.200 102.809 11.244
201712 6.446 104.110 7.780
201806 4.061 104.945 4.862
201812 2.292 105.967 2.718
201906 1.172 106.617 1.381
201912 1.455 107.917 1.694
202006 3.856 106.246 4.560
202009 0.000 107.917 0.000
202012 4.780 108.846 5.518
202103 0.000 109.496 0.000
202106 5.477 110.332 6.238
202109 0.000 111.168 0.000
202112 4.520 112.654 5.042
202203 0.000 115.069 0.000
202206 3.751 117.112 4.025
202209 0.000 119.248 0.000
202212 2.418 121.477 2.501
202303 0.000 123.148 0.000
202306 1.947 124.170 1.970
202309 0.000 125.656 0.000
202312 0.837 125.656 0.837

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genetic Technologies  (NAS:GENE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Genetic Technologies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Technologies (Genetic Technologies) Business Description

Traded in Other Exchanges
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

Genetic Technologies (Genetic Technologies) Headlines